Neoadjuvant atezolizumab meets researcher-defined safety criteria for use in combination with cisplatin plus pemetrexed and then as postsurgical maintenance therapy for people with resectable malignant pleural mesothelioma.
Strategies to improve flexibility in clinical trials may improve enrollment rates during and after the COVID-19 pandemic, according to a study presented at the IASLC 2021 World Conference on Lung Cancer.
Assessing circulating tumor DNA levels prior to initiating neoadjuvant chemoimmunotherapy for locally advanced non-small-cell lung cancer could help to identify patients likely to derive long-term benefit from treatment, suggest exploratory data.
Treatment with carboplatin and pemetrexed plus atezolizumab shows promise for people with nonsquamous non-small-cell lung cancer and asymptomatic, untreated brain metastases, phase 2 study findings indicate.
The ATLANTIS trial has found no significant overall survival improvement with the combination of lurbinectedin and doxorubicin versus chemotherapy in previously treated patients with small-cell lung cancer.
Smokers who quit after receiving a diagnosis of early-stage non-small-cell lung cancer significantly improve their likelihood of survival relative to those who continue smoking, shows a large prospective cohort study.
The addition of nivolumab plus ipilimumab to first-line chemotherapy continues to be beneficial for patients with metastatic non-small-cell lung cancer with longer follow-up, show updated phase 3 trial data.
Adding nivolumab to neoadjuvant chemotherapy for resectable non-small-cell lung cancer is not associated with surgical delays or complications, show CheckMate 816 data presented at the 2021 ASCO Annual Meeting.
Five-year findings from the PACIFIC trial for patients with unresectable stage III non-small-cell lung cancer continue to show survival benefits with 1 year of durvalumab therapy versus placebo after platinum-based chemoradiotherapy.
People with stage II–IIIA non-small-cell lung cancer derive a significant disease-free survival benefit from adjuvant treatment with atezolizumab versus best supportive care, according to phase 3 trial results.
The addition of pembrolizumab to pemetrexed–paclitaxel chemotherapy provides durable survival advantages for treatment-naïve patients with metastatic, nonsquamous non-small-cell lung cancer, the final protocol-specified analysis of KEYNOTE-189 has confirmed.
The NIBIT-MESO-1 trial suggests that retreatment with tremelimumab plus durvalumab could be a viable option for patients with unresectable mesothelioma who progress after initially benefiting from the combination.